Description

Elamipretide TFA (also known as MTP-131 TFA, RX-31 TFA, or SS-31 TFA) is the trifluoroacetate salt form of Elamipretide, a mitochondria-targeting tetrapeptide that binds selectively to cardiolipin in the inner mitochondrial membrane. This interaction stabilizes mitochondrial structure and enhances bioenergetics, leading to improved ATP production, reduced oxidative stress, and protection against apoptosis.

Research interest in Elamipretide TFA has expanded due to its ability to ameliorate myocardial infarction, enhance renal function, and safeguard neurons against inflammatory and oxidative damage. By preserving mitochondrial integrity, Elamipretide TFA supports studies related to cardiovascular disease, kidney injury, neurodegeneration, and age-related mitochondrial dysfunction.

This product is manufactured under GMP-certified conditions, ensuring consistency, purity (?99%), and reliability for advanced research models. Both wholesale and retail orders are available to meet diverse laboratory needs.

For laboratory research only. Not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Elamipretide TFA is designed to penetrate the mitochondrial membrane and bind to cardiolipin, a phospholipid essential for maintaining cristae structure and respiratory chain function. This peptide helps to:

1. Stabilize mitochondrial membranes – By binding to cardiolipin, Elamipretide TFA prevents its peroxidation and preserves structural integrity.

2. Enhance ATP production – Stabilization of the electron transport chain improves oxidative phosphorylation efficiency.

3. Reduce oxidative stress – By lowering reactive oxygen species (ROS), the compound protects cells from mitochondrial dysfunction.

4. Inhibit apoptosis pathways – Reduced cytochrome c release from mitochondria contributes to cellular survival.

Research Applications:

• Cardiovascular Studies: Shown to reduce myocardial infarct size and improve cardiac performance in ischemia/reperfusion injury models.

• Renal Function Research: Investigated for its potential to protect kidneys from ischemia-induced and drug-induced injury.

• Neurological Research: Protects neurons from oxidative stress, with applications in models of Parkinson’s disease, Alzheimer’s, and stroke.

• Mitochondrial Dysfunction Studies: Used as a model compound in aging research and in disorders involving mitochondrial abnormalities.

• Inflammation and Oxidative Injury: Reduces systemic and localized oxidative burden, making it useful in multi-organ injury studies.

Through these mechanisms, Elamipretide TFA has become a valuable tool for experimental research into mitochondrial biology, disease pathogenesis, and potential therapeutic interventions.

Side Effects (For Reference in Models)

In preclinical and clinical research settings, Elamipretide TFA has been associated with the following observed effects:

• Mild injection-site reactions (localized redness, swelling in model organisms).

• Transient gastrointestinal disturbances in experimental subjects.

• Possible hypotension due to vasodilatory properties in cardiovascular studies.

• Headache or fatigue in some animal and early-phase trial observations.

These effects are context-specific to research models and may vary depending on the dosage and experimental design.

Important: Elamipretide TFA is provided strictly for laboratory research. It is not approved for medical, clinical, or veterinary use.

Disclaimer

Elamipretide TFA is intended for laboratory research use only. It is not a drug, food additive, or household chemical. Not for human or veterinary use. All handling should follow appropriate laboratory safety procedures.

Keywords

Elamipretide TFA CAS 1606994-55-1, Elamipretide peptide, MTP-131 TFA, SS-31 TFA, RX-31 TFA, mitochondria-targeting peptide, mitochondrial research compound, cardiolipin-binding peptide, GMP peptide supplier, cardioprotection research, renal protection peptide, oxidative stress research chemical